FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

FibroBiologics (NASDAQ:FBLG) entered agreements for a private placement of 4,081,633 shares (or pre-funded warrants) plus series A and short-term series B warrants, all priced at-the-market at $0.735 per share under Nasdaq rules.

The deal is expected to raise about $3.0 million upfront, with up to approximately $6.0 million in additional gross proceeds if all warrants are exercised. Closing is expected on or about June 29, 2026, with net proceeds earmarked for working capital and general corporate purposes.

Positive

• Approximately $3.0 million in upfront gross proceeds from private placement
• Up to approximately $6.0 million additional gross proceeds possible from warrant exercise
• Placement priced at-the-market at $0.735 per share under Nasdaq rules
• Series A warrants have up to five-year potential exercise window after approvals

Negative

• Issuance of up to 12,244,899 shares (shares plus warrant shares) increases share count
• Additional $6.0 million proceeds depend on optional warrant exercises, not guaranteed
• Warrant exercisability contingent on future stockholder approval and effective registration

News Market Reaction – FBLG

+12.67%

7 alerts

+12.67% Session close to close

+13.1% Peak Tracked

-15.6% Trough Tracked

$3.82M Market Cap

1.4x Rel. Volume

In the Jun 26 session, FBLG gained 12.67%, reflecting a significant positive market reaction. Argus tracked a peak move of +13.1% during that session. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with F...

Analysis

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with FibroBiologics’ history of generally constructive responses to news. The financing adds up to $9.0 million in potential proceeds but introduces new share and warrant overhang that could weigh if sentiment shifts.

Key Figures

Upfront gross proceeds: $3.0 million Potential warrant proceeds: approximately $6.0 million Shares in offering: 4,081,633 shares +5 more

8 metrics

Upfront gross proceeds $3.0 million Private placement initial closing

Potential warrant proceeds approximately $6.0 million If series A and B warrants fully exercised for cash

Shares in offering 4,081,633 shares Common stock (or pre-funded warrants) sold in private placement

Purchase price $0.735 per share Private placement pricing under Nasdaq at-the-market rules

Warrant exercise price $0.735 per share Series A and short-term series B warrants

Patent portfolio size 270+ patents Issued and pending patents referenced in company description

Series A warrant term five years From later of Stockholder Approval Date and Effective Date

Series B warrant term eighteen months From later of Stockholder Approval Date and Effective Date

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Patent allowance	Positive	+0.1%	USPTO notice of allowance for wound-healing fibroblast spheroid patent.
Jun 16	Clinical trial update	Positive	-9.3%	Progress on Phase 1/2 CYWC628 dosing and manufacturing for diabetic foot ulcers.
Jun 03	Clinical trial start	Positive	+1.9%	First patients enrolled and dosed in Phase 1/2 CYWC628 trial in Australia.
May 22	Preclinical data	Positive	+0.0%	Preclinical psoriasis data showing durable immunomodulation with fibroblast spheroids.
May 18	Patent filing	Positive	+3.8%	New provisional patent for oral fibroblast and fibroblast‑derived therapeutics platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent FibroBiologics news has usually seen modestly aligned price moves, with one notable selloff on a clinical trial update.

Key Terms

at-the-market, private placement, warrants, regulation d, +2 more

6 terms

at-the-market financial

"a private placement priced at-the-market under Nasdaq rules"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

private placement financial

"today announced that it has entered into definitive agreements for the purchase and sale"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

warrants financial

"series A warrants to purchase up to 4,081,633 shares of common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

regulation d regulatory

"and/or Regulation D promulgated thereunder and, along with the shares"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

section 4(a)(2) regulatory

"under Section 4(a)(2) of the Securities Act of 1933, as amended"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

resale registration statement regulatory

"the Effective Date of the resale registration statement registering the shares"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants

HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,081,633 shares of common stock and short-term series B warrants to purchase up to 4,081,633 shares of common stock at a purchase price of $0.735 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and the short-term series B warrants will have an exercise price of $0.735 per share and will be exercisable on or after the effective date of stockholder approval (the "Stockholder Approval Date") of the issuance of the shares of common stock upon exercise of the warrants (the "Stockholder Approval"). The series A warrants will expire five years from the later of the Stockholder Approval Date and the effective date (the "Effective Date") of the resale registration statement registering the shares of common stock issuable upon exercise of the series warrants, and the short-term series B warrants will expire eighteen months from the later of the Stockholder Approval Date and the Effective Date. The private placement is expected to close on or about June 29, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering are expected to be approximately $3.0 million, before deducting placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A and series B warrants, if fully exercised on a cash basis, will be approximately $6.0 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the completion of the offering; the satisfaction of customary closing conditions related to the offering; the anticipated use of proceeds therefrom; the potential exercise of the series warrants prior to their expiration and potential proceeds therefrom, and the receipt of Stockholder Approval. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics' ability to manufacture its product candidates; (e) FibroBiologics' ability to conduct clinical trials; and (f) market and other conditions. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com 

Investor Contact:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com 

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-announces-up-to-9-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-302811523.html

SOURCE FibroBiologics, Inc.

FAQ

What did FibroBiologics (NASDAQ:FBLG) announce in its June 26, 2026 private placement?

FibroBiologics announced a private placement of common stock, pre-funded warrants, and series A and B warrants expected to raise about $3.0 million upfront. According to the company, pricing is $0.735 per share, with potential total gross proceeds of roughly $9.0 million including warrant exercises.

How much capital could FibroBiologics (FBLG) raise from the June 2026 private placement and warrants?

FibroBiologics expects about $3.0 million in initial gross proceeds, with up to roughly $6.0 million more if all warrants are exercised for cash. According to the company, total potential gross proceeds from this financing are approximately $9.0 million before fees and expenses.

What are the key terms of the FibroBiologics (FBLG) series A and B warrants issued in June 2026?

The series A and short-term series B warrants both have a $0.735 exercise price and cover up to 4,081,633 shares each. According to FibroBiologics, series A warrants expire five years after approvals, while series B warrants expire eighteen months after the same dates.

When is the FibroBiologics (FBLG) June 2026 private placement expected to close?

The private placement is expected to close on or about June 29, 2026, subject to customary conditions. According to FibroBiologics, H.C. Wainwright & Co. is acting as exclusive placement agent for this at-the-market priced transaction under Nasdaq rules.

How will FibroBiologics (FBLG) use the proceeds from the June 2026 private placement?

FibroBiologics plans to use net proceeds for working capital and general corporate purposes. According to the company, approximately $3.0 million in gross proceeds is expected initially, with further funds possible if investors exercise the series A and B warrants for cash.

Are the securities in FibroBiologics (FBLG) June 2026 private placement registered under the Securities Act?

The securities are being issued in a private placement under Section 4(a)(2) and/or Regulation D and are not registered. According to FibroBiologics, resale will require an effective registration statement or a valid exemption, and a resale registration statement will be filed.